Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
1877.HK Stock Price Chart
Explore Shanghai Junshi Biosciences Co., Ltd. interactive price chart. Choose custom timeframes to analyze 1877.HK price movements and trends.
1877.HK Company Profile
Discover essential business fundamentals and corporate details for Shanghai Junshi Biosciences Co., Ltd. (1877.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Dec 2018
Employees
2.58K
Website
https://www.junshipharma.comCEO
Cong Li
Description
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
1877.HK Financial Timeline
Browse a chronological timeline of Shanghai Junshi Biosciences Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Oct 2025
Earnings released on 26 Aug 2025
Earnings released on 25 Apr 2025
EPS came in at -$0.26 , while revenue for the quarter reached $536.71M .
Earnings released on 27 Mar 2025
EPS came in at -$0.38 , while revenue for the quarter reached $720.32M .
Earnings released on 29 Oct 2024
EPS came in at -$0.32 , while revenue for the quarter reached $536.84M .
Earnings released on 30 Aug 2024
EPS came in at -$0.39 , while revenue for the quarter reached $435.20M .
Earnings released on 30 Apr 2024
EPS came in at -$0.31 , while revenue for the quarter reached $411.99M .
Earnings released on 29 Mar 2024
EPS came in at -$0.98 , while revenue for the quarter reached $571.21M .
Earnings released on 30 Sept 2023
EPS came in at -$0.45 , while revenue for the quarter reached -$718.30M .
Earnings released on 30 Jun 2023
EPS came in at -$0.50 , while revenue for the quarter reached $448.30M .
Earnings released on 31 Mar 2023
EPS came in at -$0.63 surpassing the estimated -$0.75 by +16.48%, while revenue for the quarter reached $291.25M .
Earnings released on 31 Dec 2022
EPS came in at -$0.96 , while revenue for the quarter reached $1.66B .
Earnings released on 30 Sept 2022
EPS came in at -$0.83 , while revenue for the quarter reached -$1.04B .
Earnings released on 30 Jun 2022
EPS came in at -$0.65 , while revenue for the quarter reached $370.55M .
Earnings released on 31 Mar 2022
EPS came in at -$0.54 , while revenue for the quarter reached $775.82M .
Earnings released on 31 Dec 2021
EPS came in at -$0.45 , while revenue for the quarter reached $1.60B .
Earnings released on 30 Sept 2021
EPS came in at -$0.60 , while revenue for the quarter reached $728.45M .
Earnings released on 30 Jun 2021
EPS came in at -$0.45 , while revenue for the quarter reached $599.52M .
Earnings released on 31 Mar 2021
EPS came in at $0.51 , while revenue for the quarter reached $1.91B .
Earnings released on 31 Dec 2020
EPS came in at -$0.75 , while revenue for the quarter reached $693.54M .
Earnings released on 30 Sept 2020
EPS came in at -$0.71 , while revenue for the quarter reached $497.13M .
1877.HK Stock Performance
Access detailed 1877.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.